Table 2 Clinical baseline characteristics and neoadjuvant treatment modalities in the TRG 0 and TRG 1–3 groups.
Characteristic | TRG 0 (n = 174) | TRG 1-3 (n = 500) | P |
|---|---|---|---|
Age, mean ± SD, years | 55.41 ± 11.50 | 56.84 ± 10.92 | 0.145 |
Sex (%) | 0.250 | ||
Male | 118(67.8) | 362(72.4) | |
Female | 56(32.2) | 138(27.6) | |
Pre-treatment CEA(ng/ml)(%) | 0.012 | ||
<5 | 105(60.3) | 252(50.4) | |
≥5 | 58(33.4) | 223(44.6) | |
NA | 11(6.3) | 25(5.0) | |
Distance from anal verge(cm)(%) | 0.658 | ||
<5 | 82(47.1) | 217(43.4) | |
5–10 | 90(51.7) | 275(55.0) | |
>10 | 2(1.2) | 8(1.6) | |
MRI-T stage(%) | <0.001 | ||
1 | 1(0.6) | 1(0.2) | |
2 | 15(8.6) | 8(1.6) | |
3 | 129(74.1) | 377(75.4) | |
4 | 29(16.7) | 114(22.8) | |
Tumour histologic grade(%) | 0.012 | ||
Well differentiated adenocarcinoma | 15(8.6) | 58(11.6) | |
Moderately differentiated adenocarcinoma | 115(66.1) | 303(60.6) | |
Poorly differentiated adenocarcinoma | 21(12.1) | 30(6.0) | |
Signet ring cell cancer or mucinous adenocarcinoma | 1(0.6) | 6(1.2) | |
Uncertain differentiation type | 22(12.6) | 103(20.6) | |
Time interval between neoadjuvant (chemo)radiotherapy and surgery, median (IQR) (weeks) | 9.57(8.00–11.50) | 9.57(7.86–13.14) | 0.344 |
Neoadjuvant treatment modalities(%) | 0.173 | ||
Short-Course Radiotherapy+ Neoadjuvant chemotherapy | 6(3.5) | 32(6.4) | |
Long-Course Chemoradiation | 58(33.3) | 192(38.4) | |
Neoadjuvant chemotherapy+ Long-Course Chemoradiation | 13(7.5) | 41(8.2) | |
Long-Course Chemoradiation+ Neoadjuvant chemotherapy | 97(55.7) | 235(47.0) |
